1 Clinical practice guidelines for the care of patients with a chronic subdural

2 haematoma: multidisciplinary recommendations from presentation to

3 recovery

4	Stubbs DJ ¹ *, Davies BM ² *, Edlmann E ³ , Ansari A ⁴ , Bashford TH ⁵ , Braude
5	P ⁶ , Bulters D ⁷ , Camp S ⁸ , Carr G ⁹ , Coles JP ¹ , DeMonteverde-Robb D ¹¹ ,
6	Dhesi J ¹² , Dinsmore J ¹³ , Evans NR ¹⁴ , Foster E ¹⁵ , Fox E ¹⁶ , Froom I ¹⁶ ,
7	Gillespie CS ² , Gray N ¹⁷ , Grieve K ² , Hartley P ¹⁸ , Lecky F ¹⁹ , Kolias A ² ,
8	Jeeves J ¹⁶ , Joannides A ² , Minett T ²⁰ , Moppett I ²¹ , Nathanson MH ²² ,
9	Newcombe V ¹⁰ , Outtrim JG ¹ , Owen N ² , Peterman L ²³ , Ralhan S ²⁴ , Shipway
10	D^{25} , Sinha R^{26} , Thomas W^{27} , Whitfield P^3 , Wilson SR^{28} , Zolnourian A^7 ,
11	Dixon-Woods M^4 , Menon DK ¹ , Hutchinson PJ ² on behalf of the Improving
12	care in elderly neurosurgery initiative (ICENI) working group.
13	1. Perioperative, Acute, Critical, and Emergency Care (PACE) Section,
14	Department of Medicine, University of Cambridge, Cambridge, UK
15	2. Department of Clinical Neurosurgery, University of Cambridge, Cambridge,
16	UK
17	3. Department of Neurosurgery, South West Neurosurgical Centre, Plymouth, UK
18	4. THIS Institute (The Healthcare Improvement Studies Institute), Department of
19	Public Health and Primary Care, University of Cambridge, Cambridge, UK
20	5. International Health Systems Group, Department of Engineering, University of
21	Cambridge, UK. Consultant Anaesthetist, Cambridge University Hospitals NHS
22	Foundation Trust, Cambridge, UK.
23	6. CLARITY (Collaborative Ageing Research), North Bristol NHS Trust, Bristol,
24	UK
25	7. Department of Neurosurgery, University Hospital Southampton, Southampton,
26	UK

27	8.	Department of Neurosurgery, Imperial College Healthcare NHS Trust, London,
28		UK
29	9.	Neurological Alliance, London, UK
30	10.	Department of Medicine, University of Cambridge, Cambridge, UK
31	11.	Department of Pharmacy, Cambridge University Hospitals NHS Foundation
32		Trust, Cambridge, UK
33	12.	Department of Geriatric Medicine, Kings College London NHS Foundation
34		Trust, London, UK
35	13.	Department of Neuroanaesthesia, St George's Hospital, London, UK
36	14.	Department of Clinical Neurosciences, University of Cambridge, Cambridge,
37		UK
38	15.	Department of Medicine of the Elderly, NHS Lothian, Edinburgh, UK
39	16.	Patient and public representative group, Cambridge, UK
40	17.	Department of Physiotherapy, Nottingham University Hospitals NHS Trust,
41		Nottingham, UK
42	18.	Department of Physiotherapy, Cambridge University Hospitals NHS Trust,
43		Cambridge, UK
44	19.	School of Population Health, University of Sheffield, Sheffield, UK
45	20.	Department of Neurology, Cambridge University Hospitals NHS Trust,
46		Cambridge UK
47	21.	Academic Unit of Injury, Inflammation and Repair, University of Nottingham,
48		Nottingham, UK
49	22.	Department of Anaesthesia, Nottingham University Hospitals NHS Trust,
50		Nottingham, UK
51	23.	EXEP Consulting, Nottingham, UK

52	24. Department of Geriatric Medicine, Oxford University Hospitals NHS
53	Foundation Trust, Oxford, UK
54	25. Department of Geriatric Medicine, North Bristol NHS Trust, Bristol, UK
55	26. Department of Neurosurgery, Leeds General Infirmary, Leeds, UK
56	27. Department of Haematology, Cambridge University hospitals NHS Trust,
57	Cambridge, UK
58 59	28. Department of Anaesthesia, University College London Hospitals NHS Foundation Trust
60	
61	
62	Corresponding author: Dr Daniel J Stubbs
62 63	Corresponding author: Dr Daniel J Stubbs Clinical lecturer in anaesthesia, Locum Consultant in Neuroanaesthesia
62 63 64	Corresponding author: Dr Daniel J Stubbs Clinical lecturer in anaesthesia, Locum Consultant in Neuroanaesthesia Perioperative, acute, critical, and emergency care (PACE) section
62 63 64 65	Corresponding author: Dr Daniel J Stubbs Clinical lecturer in anaesthesia, Locum Consultant in Neuroanaesthesia Perioperative, acute, critical, and emergency care (PACE) section Department of Medicine, University of Cambridge
 62 63 64 65 66 	Corresponding author: Dr Daniel J Stubbs Clinical lecturer in anaesthesia, Locum Consultant in Neuroanaesthesia Perioperative, acute, critical, and emergency care (PACE) section Department of Medicine, University of Cambridge Box 93, Level 4 Addenbrooke's Hospital
 62 63 64 65 66 67 	Corresponding author: Dr Daniel J Stubbs Clinical lecturer in anaesthesia, Locum Consultant in Neuroanaesthesia Perioperative, acute, critical, and emergency care (PACE) section Department of Medicine, University of Cambridge Box 93, Level 4 Addenbrooke's Hospital Hills Road
 62 63 64 65 66 67 68 	Corresponding author: Dr Daniel J Stubbs Clinical lecturer in anaesthesia, Locum Consultant in Neuroanaesthesia Perioperative, acute, critical, and emergency care (PACE) section Department of Medicine, University of Cambridge Box 93, Level 4 Addenbrooke's Hospital Hills Road Cambridge, CB2 0QQ, UK
 62 63 64 65 66 67 68 69 	Corresponding author: Dr Daniel J Stubbs Clinical lecturer in anaesthesia, Locum Consultant in Neuroanaesthesia Perioperative, acute, critical, and emergency care (PACE) section Department of Medicine, University of Cambridge Box 93, Level 4 Addenbrooke's Hospital Hills Road Cambridge, CB2 0QQ, UK Email: djs225@cam.ac.uk

71

72 Clinical practice guidelines for the care of patients with a chronic subdural

73 haematoma: multidisciplinary recommendations from presentation to

- 74 recovery
- 75 Abstract

76 Introduction

77	A cSDH is an encapsulated collection of fluid and blood degradation products in
78	the subdural space. It is increasingly common, affecting older people and those
79	living with frailty. Currently, no guidance exists to define optimal care from
80	onset of symptoms through to recovery. This paper presents the first consensus-
81	built recommendations for best practice in the care of cSDH, co-designed to
82	support each stage of the patient pathway.

83 Methods

84	Guideline development was led by a multidisciplinary Steering Committee with
85	representation from diverse clinical groups, professional associations, patients,
86	and carers. Literature searching to identify relevant evidence was guided by core
87	clinical questions formulated through facilitated discussion with specially
88	convened working groups. A modified Delphi exercise was undertaken to build
89	consensus on draft statements for inclusion in the guideline using survey
90	methodology and an in-person meeting. The proposed guideline was
91	subsequently endorsed by the Society for British Neurological Surgeons,
92	Neuroanaesthesia and Critical Care Society, Association of Anaesthetists, British
93	Association of Neuroscience Nurses, British Geriatric Society, and Centre for
94	Perioperative Care.

95 Results

9	5	We identified that high quality evidence was generally lacking in the literature,
9	7	although randomised controlled trial (RCT) data were available to inform specific
9	8	recommendations on aspects of surgical technique and use of corticosteroids. The
9	Ð	final guideline represents the outcome of synthesising the available evidence as
10)	well as consensus-built expert opinion and patient involvement. The guideline

- 101 comprises 67 recommendations across 8 major themes, covering: presentation
- 102 and diagnosis, neurosurgical triage and shared decision-making, non-operative
- 103 management, perioperative management (including of anticoagulation), timing of
- 104 surgery, intraoperative care, postoperative care, rehabilitation and recovery.

105 Conclusions

- 106 We present the first multidisciplinary guideline for the care of patients with
- 107 cSDH. The recommendations reflect a paradigm shift in the care of cSDH,
- 108 recognising and formalising the need for multidisciplinary and collaborative
- 109 clinical management and communication and decision-making with patients
- 110 delivered effectively across secondary and tertiary care.
- 111
- 112 Keywords: guideline; chronic subdural haematoma; perioperative care
- 113

114 Introduction

115 A chronic subdural haematoma (cSDH) is an encapsulated collection of fluid, blood, 116 and blood degradation products layered between the arachnoid and dura matter coverings on the brain's surface.¹ It is a common neurological condition, most often 117 affecting older patients with other health conditions, frailty, or anti-thrombotic use.²⁻⁴ 118 Symptoms may be sub-acute in onset,² mirroring those of a slowly evolving stroke, and 119 120 can occur with or without antecedent trauma.⁵ Given its impact on patient functioning 121 and experience, it can be considered a 'sentinel' health event 6,7 similar to conditions 122 such as fractured neck of femur. 123 124 Data from both the United Kingdom (UK) and United States (US) suggest that cSDH case numbers will rise by 50% over the next two decades.^{8,9} However, while care of a 125

126 similarly vulnerable surgical population – people with fractured neck of femur – has

127 been revolutionised by guideline-led and multidisciplinary co-management supported

128 by audit, care of cSDH remains very poorly optimised. ^{10,11} No best practice guidance

129 exists. Care is delivered via complex and often fragmented systems spanning regional

130 networks and professional and organisational boundaries, with patients needing input

131 from multiple disciplines across primary, community, secondary and tertiary care that

132 may not always be well coordinated. Inter-hospital transfer is common because surgery

133 needs to be provided by adult neurosurgical services, which are concentrated in

approximately 30 locations across the UK and Ireland. ¹² Up to 90% of patients needing

surgical care for cSDH initially present to local secondary care settings, with over 40%

136 of these repatriated to their referring institution following surgery.¹³

137

138 Absence of best practice guidance and the challenges of the poorly defined and sub-

139 optimal care model are implicated in known difficulties in communication, patient

140 flow, multidisciplinary coordination, and resourcing; resulting in significant acute bed usage, patient and staff dissatisfaction, and perioperative morbidity.^{2,13,14} This 141 142 guideline seeks to address these problems by co-designing a new approach to best 143 practice. Based on current available evidence and consensus-built with professionals, 144 patients, and carers, this guidance seeks to provide a resource to inform each stage of 145 the patient journey from diagnosis, surgical triage, and referral through the perioperative 146 period and on to recovery. It has been designed to be relevant for those caring for 147 patients with cSDH both in and outside of specialist neuroscience units (NSU), and 148 those involved in planning and organising services.

149 Who do the recommendations apply to?

150 These recommendations apply to any patients diagnosed with a cSDH in secondary or 151 tertiary care in the UK, from the onset of symptoms through to recovery. In clarifying 152 "what good looks like" for this condition, they will help to reduce unwarranted variation 153 in practice and outcomes, and will be helpful in upskilling those less familiar with this 154 condition (e.g. because they are based outside tertiary neurosurgical centres). This is 155 vital, as pathway analysis has demonstrated that cSDH requires input from nearly 30 156 distinct in-patient specialities and, as a cohort, over a third of the inpatient stay is in non-specialist centres.¹³ Our guidelines also make recommendations for the care of 157 patients initially triaged to 'non-operative' management. This is a significant cohort 158 (approximately 30% of all referrals to neurosurgical teams)² but evidence to guide the 159 160 care of this group is extremely limited.

161

162 The recommendations have been co-designed to address specific challenges in the 163 perioperative care of cSDH. They should be viewed as complementary to other more 164 general guidance for the delivery of safe perioperative care, such as the Royal College

- 165 of Anaesthetists' core guidelines for the provision of anaesthetic services ¹⁵ and
- 166 guidelines on perioperative care of individuals living with frailty issued by the Centre
- 167 for Perioperative Care (CPOC).¹⁶
- 168
- 169 Our recommendations do not apply to those with acute subdural haematoma (aSDH)
- 170 which often occurs as a result of major trauma.¹⁷

171 Methods

- 172 Development of the guideline was protocol-led,¹⁸ informed by methodology used by the
- 173 UK National Institute for Health and Care Excellence (NICE)¹⁹ and the AGREE II
- 174 (Appraisal of Guidelines for Research and Evaluation) checklist.²⁰ Per protocol, ¹⁸ a
- 175 multidisciplinary Steering Committee of experts in the care of cSDH with
- 176 representation from patients and carers and relevant professional societies and
- 177 associations was convened.

178 Statement generation

- 179 Five working groups were formed to cover distinct phases of care, based on patient
- 180 journey and stakeholder identification ¹³ [Figure 1]. Participants with relevant
- 181 expertise for the working groups were recruited through professional networks,
- 182 snowball sampling, recommendation by professional society, or literature searching. In
- total, 17 different medical or allied health disciplines were represented across the
- 184 working groups, as was a patient-facing charity, the *Neurological Alliance*. Separate
- 185 patient and carer representatives were identified from two separate UK regions. Joint
- 186 working group leads were appointed, each with a neurosurgical lead paired with a
- 187 relevant other specialty lead (e.g. emergency medicine, geriatric medicine). To ensure
- 188 that recommendations were relevant to the broadly defined multidisciplinary teams,

189 clinicians from across secondary and tertiary care were purposefully included in the

190 working groups.

191

192	Separate facilitated meetings of each working group were helped to identify key clinical
193	questions specified in the PICO format (Population, Intervention, Comparator,
194	Outcome) to guide literature searching. 44 PICO questions were grouped into 12 key
195	themes and mapped to the current literature via a systematic search. GRADE
196	methodology was used to assess the evidence (supplemental material) and, where
197	possible, meta-analysis was undertaken, with some outputs already accepted for
198	publication ^{21,22} . This work, together with a parallel umbrella review of existing
199	systematic reviews ²³ , identified that most areas of cSDH care were lacking in evidence.
200	
201	The Steering Committee oversaw and reviewed outputs of the individual working
202	groups, and drafted recommendations based on evidence reviews and consultation with

203 the working groups. Evidence tables derived from literature searching and the full list of

204 PICO questions are included in supplementary material to this paper.

205 Consensus-building

206



214 represents an informed synthesis of evidence, where available, and expert opinion, a 215 necessary approach given the paucity of published research in many key clinical areas. 216 217 During the consensus meeting, evidence that had emerged since the original literature 218 searches (Summer 2022) was presented to attendees. Revisions to the guideline 219 following consensus-building exercise were approved by the Steering Committee before 220 the guideline draft was submitted for external review and endorsement by professional 221 societies. Minor wording changes suggested by this process were incorporated and 222 ratified by the Steering Committee. Full details of all changes are available in a separate 223 paper summarising our consensus-building exercise and its supplementary material.

224 Patient and public perspectives

225 Patient and carer perspectives were fundamental to the co-design approach. We

226 convened a patient and carer panel to review the PICO questions and agree the scope of

the future guideline. This session was chaired by anaesthetic (DJS), neurosurgical (EE,

BMD), nursing (JGO), and charity (GC) representatives from our Steering Committee.

229 Additional patient and carer representatives (IF, EF, JJ) who had experience of cSDH

230 care across two UK neurosurgical centres attended our in-person consensus meeting.

231 These representatives reviewed all documents pre and post meeting, participated

actively in discussions, proposed changes based on their lived experience, and had

- 233 voting rights equivalent to others.
- 234

Additional review by patient and public representatives to endorsing societies (CPOC)

highlighted how inter-hospital transfer could be distressing and disruptive to patients,

237 especially those with acute or chronic cognitive impairment. The question of whether

an advocate could accompany such patients, or whether transfers could be scheduled for

239	day (rather than night times) to help reduce distress, was raised, and will need to be
240	considered in future updates of this guideline once the relevant evidence and
241	consultation has taken place. However, in the meantime, we recognise that although
242	important, such considerations should not delay clinically urgent transfers.
243	Strength of recommendations
244	In general, statements in the guideline contain a verb and action that might be
245	performed in clinical practice. The strength of each recommendation is incorporated
246	into the text using the following definitions adopted by the National Institute for Health
247	and Care Excellence (NICE) ²⁴ .
248	• <i>Must</i> – for instance there is a legal duty to apply a recommendation or the
249	consequences of not following a recommendation is extremely serious
250	• <i>Should</i> –the intervention will do more good than harm for the vast majority of
251	patients
252	• <i>Could</i> – will do more good than harm for most patients.
253	• <i>Consider</i> is used to indicate that the recommendation is less strong than a
254	'should' recommendation with more closely matched risks and benefits.
0.5.5	
255	Terminology and phrasing
256	At certain points in the text, we have used certain phrases to identify recurrent concepts.
257	Sometimes we have had to assign certain decisions (such as judging what is
258	'significant' or 'urgent') to clinical decision-makers because evidence does not exist to
259	define accurate thresholds.
260	
261	Throughout, we use the term 'patient's advocates' to encompass the many different
262	individuals who may be able to provide information about a patient's wishes or health.

263	This does not reflect a specific legal term (such as an 'independent mental capacity
264	advocate') but instead is intended to encompass the broadest definition of a patient's
265	'relevant others'. This includes (but is not limited to) a patient's next-of-kin, family, or
266	close friends. These individuals may vary from person to person. Understanding this
267	and communicating with the correct individual(s) where appropriate is an important
268	expectation.
269	
270	We have used the phrase 'geriatrician' and 'geriatric medicine' to identify medical

- 271 specialists in the care of older patients. We recognise that this term is sometimes
- criticised, and was the subject of much debate in our consensus meeting. In the end, we
- adopted it following the input of the multiple representatives from this discipline on our
- steering group, and because it is the term adopted by the relevant professional society in
- the United Kingdom the 'British Geriatrics Society'.

276 **Recommendations**

277 In total we make 67 statements, across 8 major themes.

278 1: Presentation, diagnosis, natural history, initial decision-making, and

279 *transfer*

280 1.1 Presentation and diagnosis

a)	Consider a cSDH in patients who have any of the following, progressively
	worsening over days to weeks:
	• Headache
	Speech disturbance

	Unsteadiness or falls
	• Focal neurology (such as one-sided limb or facial weakness)
	• Confusion or reduced consciousness level.
b)	Less commonly cSDH can cause sudden onset, and/or transient symptoms,
	including seizures.
	Isolated confusion is less specific for cSDH than other symptoms, and other causes
c)	should also be considered in the differential diagnosis.
	Many patients with cSDH have some pre-existing functional or cognitive
d)	impairment, so it is important to establish their baseline so changes from this can be
	identified.
	A collateral history should be sought if the patient is unable to provide a detailed
e)	description of their symptoms or onset.
	Patients with a suspected cSDH should receive diagnostic neuro-imaging, typically
f)	a non-contrast CT
	In cases of bilateral cSDH, where there is suspicion of intracranial hypotension (e.g.
g)	due to CSF leak), the neurosurgical team should consider seeking specialist (e.g
	neurosurgical subspecialty or neuroradiology) opinion and further investigation
L	

281

Patients identified to have a cSDH should be referred urgently to Neurosurgery. Referral should include a clear description of:
• Symptoms (including the presence or absence of common symptoms related to a cSDH and their time course. This includes; focal neurology, headache, or cognitive change)
The Glasgow coma score (including its breakdown and trajectory)Any history of prior trauma
• The patient's prior functional baseline (both physical and cognitive), whether there has been a change from this, and if there are any
 Presence of any advanced directives, RESPECT plan, ceilings of care or
An assessment of the patient's frailty
 Presence of any haemostatic concerns (including coagulopathy, platelet dysfunction, anticoagulant, or antiplatelet use) Presence of any acception that is a second se
 Presence of any co-existent me-initing miness Diagnostic imaging should be made available by the referring hospital at the time of referral for neurosurgical review.
Many Neurosurgical services have adopted electronic referral systems. The
referring clinician should judge whether the clinical circumstances require an additional discussion, taking into account local guidelines.

284 1.3 Additional investigations

a)	Patients diagnosed with a cSDH should receive appropriate additional						
	investigations that may inform adjuvant management, inform perioperative						
	optimisation, or exclude competing causes of symptoms. These should include:						
	• Full blood count						
	• Coagulation parameters (including PT, APTT, and Fibrinogen)						
	Renal function						
	• Electrolytes (including Na and K)						
	• Electrocardiogram (ECG)						
	Other investigations should be guided by clinical need following consideration of						
	patient history, examination, and the results of other investigations.						
	Where abnormalities are found, optimisation should begin at the point of						
	diagnosis.						

285 2: Neurosurgical triage, shared decision-making, and inter-hospital transfer

286 2.1 Shared decision-making

287

a) Following the diagnosis of a cSDH, efforts should be made to share decisions around treatment options with patients and their advocates. They should be provided with sufficient information to inform decision-making, including an understanding of the

risks and benefits of different treatment options.

288

289 2.2 Indications for surgery

a)	Surgery should be considered in patients with symptomatic cSDH
b)	Consider surgery in patients with minimal or no symptoms of a cSDH, but with
	radiological evidence of a large volume cSDH with mass effect (e.g. significant
	midline shift > 5mm).

290

291 2.3 Adjuvant therapies

a)	Corticosteroids should not be used to treat symptomatic cSDH, either for non- operative management or as an adjuvant to operative management.
b)	There is insufficient evidence to support the routine use of statins, ACE-inhibitors or other proposed disease-modifying treatments in the management of cSDH. Whilst this does not preclude their use for other co-existing indications (e.g. hypertension or heart disease), their use for cSDH should be restricted to a research context.
c)	There is insufficient evidence to support the routine use of Tranexamic Acid for the treatment of cSDH. Whilst this does not preclude its use for other co-existing indications (e.g. peri-operative coagulopathy), the routine use of Tranexamic Acid should be restricted to a research context.

> d) There is insufficient evidence to support the routine use of middle meningeal artery embolization in the treatment of cSDH. Where it is used, patients should receive structured follow-up to inform ongoing appraisal of the treatment and we recommend that this intervention should be performed within a research context.

292

293 2.4 Inter-hospital transfer

a) If patients diagnosed with a cSDH require inter-hospital transfer, decisions around urgency of transfer and escort requirements should be informed by consideration of patient, surgical, and institutional factors, with due reference to established guidelines for the transfer of brain-injured patients ²⁵.
 b) Following patient consent, or due consideration of best interests for those unable to consent, the referring team should ensure a nominated patient advocate (e.g. next-

of-kin) is updated on the transfer, and should ensure their contact details are

294

295 3: Patients triaged to initial non-operative management

provided in the transfer documentation.

296 3.1 Management of other conditions

297

a) Where the neurosurgical opinion is that the cSDH is incidental (i.e. not associated with a patient's presenting symptoms), further investigation and management should be conducted by the referring team to identify and treat alternative

conditions.		

3.2 Anticoagulation

a)	In the absence of direct evidence on optimum anticoagulant management in patients
	with cSDH not undergoing surgery, an individualised assessment of risks and
	benefits of the discontinuation of anticoagulation should be made, considering
	patient and surgical factors, the risk of haematoma expansion, and the risk of
	thrombosis. This may require input from multiple distinct specialties, but
	ultimately is a shared decision between the patient (or their advocates if they lack
	capacity) and their lead/responsible healthcare professional.

3.3 Location and coordination of care

a)	For patients triaged to non-operative care: The choice of admitting or coordinating					
	team and the appropriate location of care should be made based on a consideration					
	of the patient's co-existent frailty, disability and acute treatment requirements. The					
	decision should not by default follow pathways that are based solely on aetiology					
	(e.g. trauma), and as such bespoke local guidance may be required. Patients should					
	be assessed for and offered tailored rehabilitation if necessary.					
b)	For patients in whom surgical intervention would not provide benefit due to the					
	severity of their neurological condition or where this may otherwise represent an					
	end-of-life diagnosis, consider specialist input from palliative care.					

a)	There is no direct evidence to inform the timing or conduct of routine interval imaging for cSDH, and it should be decided on a case-by-case basis.
b)	If follow-up to monitor the evolution and impact of the cSDH in 'non-operative' cases is felt necessary by neurosurgery, a plan should be agreed with the patient's local hospital
c)	Patients and their advocates should be provided with clear information informing them of the condition and its impact, and any symptoms or signs that should prompt them to seek further medical help, including how this should be achieved.

4: Perioperative management

4.1 Consideration of perioperative risk and consent

a)	Patients admitted with a cSDH should be screened for frailty using a validated tool
	(such as the clinical frailty scale) and, if appropriate (e.g. $CFS \ge 5$), be reviewed by
	a geriatrician and their care guided by comprehensive geriatric assessment (CGA)
	Prior to surgery, all patients should be reviewed by an anaesthetist with appropriate
b)	experience in the care of patients with cSDH.
	For patients without mental capacity the neurosurgical team should, where possible,
c)	update and discuss treatment plans with the patient's advocates (such as their next of
	kin or family)

308

309 4.2 Multidisciplinary care

310

	Care should be delivered in a manner that facilitates the input of all required
a)	specialties to deliver integrated multidisciplinary care. This is especially important
	for patients who are living with frailty.

311

313

312 4.3 Identification of delirium

	Postoperatively, patients with cSDH, especially those with persistent, or new,
a)	confusion should be screened for delirium with a validated tool (such as the 4-AT)

314 *4.4 Investigations*

a)	For patients transferred from another hospital, referring teams should include the patient's latest investigations with transfer documents. This includes ensuring radiological investigations are available to clinicians in receiving hospitals.
b)	Subject to appropriate verification, consider using investigation results provided by other institutions as an initial basis for clinical decision-making within the Neurosciences Unit (NSU), rather than undertaking repeats.
c)	For burr hole drainage procedures, where expected blood loss is low and the patient has normal haemostatic reserve, consider performing without a group and save.

316

317	4.5 Perioperative	management of	f antithrombotic	medication
-----	-------------------	---------------	------------------	------------

a)	There is a lack of evidence to make definitive recommendations in relation to the
	perioperative management of antithrombotic medications including:
	• The timing of recommencement after surgery
	• Cessation (short and long term)
	• The need for expedited reversal of antithrombotic effects
	• Optimal timing of VTE chemoprophylaxis
	All perioperative decisions on the management of anticoagulant or antiplatelet
	medications should therefore be made following an individualised consideration of
	risks and benefits. Preoperatively this includes consideration of the urgency of
	surgery.
	This decision may require input from multiple distinct specialties, but ultimately is a
	shared decision between the patient (or their advocates if they lack capacity) and
	their lead/responsible healthcare professional.
b)	Consider pharmacological reversal of anticoagulant agents.
c)	Consider the use of a platelet transfusion alongside surgery in patients still under the
	effects of anti-platelet medication only after due consideration of the potential risks
	of the use of blood products and the urgency of surgery. Although common
	practice, evidence for this approach is lacking and should ideally be subject to
	further research.

318

319 5: Timing and planning of surgery

320 5.1 Timing of surgery

a)	Indications for urgent surgery includes the presence of significant neurological
	deficits, such as deteriorating conscious level (with or without pupillary
	abnormalities) or new, or progressive, focal neurology.
b)	Radiological signs (such as significant midline shift or presence of bilateral cSDH)
	should also be considered as part of decision-making and scheduling.
c)	In patients awaiting surgery, neurological observations should be performed at an
	appropriate frequency to ensure surgery can be expedited if the clinical situation
	changes. Suitable type and frequency of observation may be guided by the NICE
	Head Injury guidance ²⁶ .

321

322 5.2 Out of hours operating

a)	Where possible, surgery for patients with cSDH should occur within core operating
	hours.
	Such considerations should never over-rule the clinical assessment of the need for
	urgent surgery and should be mindful of the potential for harm from prolonged
	immobility and fasting accordially in frail nations
	miniounity and fasting, especially in man patients.

323

324 5.3 Staff seniority

a)	Surgical and anaesthetic care of patients with cSDH should be delivered by



326

327 6: Surgical and anaesthetic care

328 6.1 Surgical care

a)	Surgery should include the placement of a temporary drain, either subdural or subgaleal where safe to do so
b)	Burrhole drainage with the use of a drain should be considered as first-line surgical management.
c)	Drainage via a craniotomy is an option, and may be required in selected cases.
d)	Irrigation fluids should be warmed to body temperature.

330 6.2 Anaesthesia

329

a)	Surgery for cSDH can be performed under either general or local anaesthesia (with or without sedation).
b)	Intraoperative monitoring should comply with recommendations from professional bodies (such as the Association of Anaesthetists ²⁷) and be individualised based on a full consideration of patient and operative factors.
c)	In line with relevant national recommendations on the care of frail patients undergoing surgery ¹⁶ , due consideration should be given to the maintenance of intraoperative physiological homeostasis, including maintenance of normothermia and individualised blood pressure targets.

332

331

333 7: Postoperative care

334 7.1 Location and delivery of care

Ī	a)	Patients should be cared for in a post-anaesthesia care unit by staff trained in the
		care of patients who have undergone neurosurgery.
	b)	Following post-anaesthesia care, patients should initially be cared for in a specialist
		neurosurgical ward, with staff trained and experienced in the care of patients with
		cSDH (e.g. care and monitoring of post-operative drains).
	c)	Post-surgical physiological observations should be conducted in line with published
		national recommendations (e.g. NICE head injury guidelines) ²⁶
	d)	Postoperatively, all patients should be reviewed by a suitably experienced member
		of the neurosurgical team within 24 hours.
		This review should ensure planning is in place for:
		• Specialist geriatric medicine review in patients aged 65 or over, or
		with a clinical frailty score (CFS) of 5, with care guided by the
		principles of the comprehensive geriatric assessment (CGA)
		• Antithrombotic management (including timing of VTE
		chemoprophylaxis and, if applicable, management of long-term anti-
		thrombotics)
		• Drain removal and wound care
		• Referral to, or involvement of, other in-hospital specialties
		• Rehabilitation

	Hospital discharge or repatriation
335	

336 7.2 Drain management

a)	Decisions on drain removal should be made by suitably experienced staff. Based on
	available evidence, this would normally occur between 24-48 hours after surgery.

337

338 7.3 Postoperative imaging

a)	Postoperative imaging should not be routinely performed but should be requested if a clinical concern arises.
b)	Postoperative imaging can be considered to inform decision-making around long- term anticoagulation.

339

340 7.4 Post-operative mobilisation

	a)	Bedrest is not advised following surgery for a cSDH. Patients should be mobilised
		and encouraged to perform a range of activities as soon as safely possible following
		surgery.
	b)	All patients should be assessed for ongoing rehabilitation requirements within 48
		hours of surgery.
341		
342		
343		
344		
345		

346 *7.5 Thromboprophylaxis*

a)	Consider commencing chemoprophylaxis for venous thromboembolism (VTE) 24-
	48 hours following surgery and 6 hours after the removal of any post-operative
	drain

347 8: Rehabilitation and recovery

348 8.1 Repatriation

a)	For patients transferred from other institutions, the potential for repatriation must
	be identified at the point of neuroscience unit admission.
	Repatriation should only occur when a patient:
	• Has had any postoperative drain safely removed
	• Requires no further inpatient neurosurgical care
	• Is medically stable for transfer
	• Has a complete discharge letter as outlined in later sections of this
	guideline [8.2a]
	Consider accepting referrals for repatriation up to 48 hours before a patient is
	expected to meet these criteria to minimise hospital stay.
b)	Neuroscience networks should work towards referral processes that expedite
	transfer, to improve patient experience, specialist bed utilisation and minimise a
	patient's in-hospital stay.

c)	Receiving specialities should be selected based on their ability to meet the medical		
	and rehabilitation needs of individuals with cSDH (many of whom are frail).		
	Examples of appropriate teams might include Neurology, Geriatric, or Stroke		
	Medicine.		
	These arrangements should be incorporated into local neuroscience network		
	policies.		
d)	Following appropriate consent, or consideration of best interests in those who lack		
	capacity, the neurosurgical team should contact the family or other advocate to		
	notify them of their relative's discharge, and ensure they are familiar with any		
	onward care plans.		

349

350 8.2 Discharge communication

a)	On discharge or transfer from a neurosurgical centre, all patients must have a
	discharge letter produced, including recent investigation results and onward
	recommendations, to ensure safe handover of care.
	Consider, as applicable, recommendations relating to:
	• Driving and that patients must contact their licensing authority
	(E.g. The Driver and Vehicle Standards Agency (DVSA) in the
	UK)
	• Medication management (including managing anticoagulation,
	venous thromboembolism chemoprophylaxis, and anti-epileptics)
	• Wound care / removal of sutures

Rehabilitation requirements
• Return to work or specific leisure activities (if applicable)
• Outpatient neurosurgical follow-up
• Contact procedures for further routine or emergency (24/7)
neurosurgical advice. Out of hours this may require attendance at,
or advice from, a patient's local emergency department
As well as being forwarded to the patient's general practitioner, patients should
also receive a copy for their own records.

352 8.3 Recurrence of symptoms and detection of surgical complications

a)	Patients experiencing a relapse in their symptoms should undergo an urgent CT. If
	they are an outpatient, this should be via their local emergency department. If a
	cSDH is identified it should be discussed with Neurosurgery following the steps
	outlined in this guideline.
b)	Patients experiencing features of a wound breakdown, or an infection of unknown
	origin, should undergo a CT Head with and without contrast, have a recent Full
	Blood Count and C-Reactive Protein Result, and be discussed with Neurosurgery.
	If they are an outpatient, this should be via their local emergency department.

353

351

354 Discussion

- 355 This document provides the first comprehensive, integrated set of recommendations as
- to what constitutes best practice in the care of cSDH, developed through novel,
- 357 transparent, and robust methods. This section summarises key information pertaining to
- 358 development and interpretation of these recommendations, which are largely consistent
- 359 with the AGREE II checklist 20 .

360 *Literature support*

- 361 Our reviews of the evidence found that published literature on which to base
- 362 recommendations relating to non-surgical aspects of cSDH care were lacking, as
- 363 summarised in our published umbrella review of systematic reviews ²³. The chosen
- 364 wording of each statement in the guidance therefore reflects the integration of all
- 365 available evidence (including expert opinion and consultation through the consensus-
- 366 building exercise) by the Steering Committee. The phrasing reflects the strength of our
- 367 recommendations, consistent with NICE approaches 24 .
- 368
- 369 Of 73 published systematic reviews identified, 63 (86%) related to surgery or the
- 370 management of related complications. For some surgical issues, high quality evidence,
- 371 including randomised controlled trials (RCTs), was available to inform practice, for
- example relating to the use of subdural drains (recommendation 6.1a). ^{28–30} Recent

373 RCTs have also explored the role of adjunctive corticosteroids,^{31,32} based on increased

374 understanding that formation and maintenance of a cSDH reflects a chronic

- 375 inflammatory process.¹ These trials broadly showed that the risks of using
- 376 corticosteroids outweighed any observed benefit, meaning it was possible to make firm
- 377 recommendations relating to their use (**recommendation 2.3a**).
- 378

379 Research gaps and areas of emerging evidence

380	We identified that cSDH is an area of active research, with a systematic review of
381	registered and running RCTs in cSDH ³³ identifying 26 ongoing RCTs in 2020.
382	Emerging trials are mainly focusing on surgical techniques and adjunctive medical
383	therapies (including steroids and tranexamic acid). However, our Steering Committee
384	identified research gaps that require urgent examination, as is apparent from the
385	published umbrella review. ²³ Nine key areas emerged during the guideline
386	development process as particular priorities: relevance of a national registry/audit,
387	antithrombotic management, communication strategies, population and perioperative
388	risk, natural history of non-operative cSDH, impact of protocolised multidisciplinary
389	care, mode of anaesthesia, middle meningeal artery embolisation, and adjuvant medical
390	therapies.
391	MMA embolisation, a radiological treatment that has been gaining popularity as an
392	adjunctive or single intervention for patients with cSDH, ³⁴ was an area of keen debate
393	during guideline development. The Steering Committee are aware that several trials
394	have reported early results, but, at the time of guideline publication, none was available
395	as a peer-reviewed publication. At our consensus meeting in November 2023, we
396	agreed therefore that MMA should only be used within a research context. This is in
397	
	keeping with subsequently published recommendations from NICE in December
398	keeping with subsequently published recommendations from NICE in December 2023. ³⁵ We recognise that evidence in this field is rapidly emerging and it will be

400 *Implementation*

401 Implementing guidelines into practice is challenging.³⁶ The co-design methodology,

402 and engagement of the wider professional community throughout, is likely to be helpful

403 in securing professional support for the recommendations, but many other

404	considerations are relevant. To begin exploring influences on implementation in more
405	detail, we have launched a consultation survey of professionals and healthcare managers
406	to identify core challenges, and examples of pre-existing good practice. ³⁷ These
407	findings will provide early pilot data to inform future implementation of the
408	(necessarily) complex interventions that will be required to enact these
409	recommendations in practice.
410	
411	It is vital that any such implementation is done in a manner that provides evidence as to
412	the effectiveness of these recommendations while developing an infrastructure to track
413	their impact in a manner analogous to that already used in conditions such as hip

414 fracture.³⁸

415 *Planned updates*

416 The first scheduled review of this guideline is November 2026 (3 years from the date of 417 the final consensus meeting). Review will be jointly led by the Society of British 418 Neurological Surgeons and Neuroanaesthesia and Critical Care Society, who will liaise 419 with other endorsing societies to ensure multidisciplinary oversight and review of new 420 evidence.

421 Conclusions

422 These guidelines offer a comprehensive set of recommendations for the

423 multidisciplinary care of patients diagnosed with a cSDH. High quality evidence is

424 currently lacking in many areas, so these recommendations reflect both the available

- 425 evidence and a distillation of consensus opinion from the Steering Committee and the
- 426 wider professional community, as well as patients and carers. If implemented in full,
- 427 they would stimulate a paradigm shift in the care of patients with a cSDH, bringing the

- 428 care of this complex and vulnerable cohort in line with other high-risk surgical groups.
- 429 Further work will ensure the guideline is maintained in line with emerging evidence and
- 430 explore routes to implement, evidence, and audit these recommendations in practice.

431 **Funding**

- 432 This project was funded by the Association of Anaesthetists (WKR0-2021-0014) and
- 433 the Addenbrooke's charitable trust (ACT #900268). The modified Delphi exercise
- 434 and Mary Dixon-Woods' contribution was supported by The Health Foundation's grant
- 435 to the THIS institute. The Health Foundation is an independent charity committed to
- 436 bringing about better health and health care for people in the UK.
- 437

438 Acknowledgements

439 Contributions

440 DJ Stubbs and BM Davies contributed equally to the generation of this guideline and should be441 considered joint first authors.

442 *Review and endorsement*

- 443 These recommendations have been separately reviewed and endorsed by the following national444 professional organisations:
- Society for British Neurological Surgeons
- Neuroanaesthesia and Critical Care Society (NACCS)
- Association of Anaesthetists (AoA)
- British Association of Neuroscience Nurses (BANN)
- British Geriatric Society (BGS)
- Centre for Perioperative Care (CPOC)

- 451 We are grateful to the council members of these organisations for their time and expertise in
- 452 reviewing and refining these guidelines. Representation from these societies to the guideline
- 453 steering committee was provided by; PW and PJAH (SBNS), SW and JPC (NACCS), MN
- 454 (AoA), JGO (BANN), DS (BGS), JD (CPOC).

455 Group authorship statement: the Improving care in elderly neurosurgery

- 456 initiative (ICENI) group
- 457 Adegboyega G, Department of Clinical Neurosciences, University of Cambridge,
- 458 Cambridge, UK
- 459 Amarouche M, Department of Neurosurgery, Oxford University Hospitals NHS Trust,
- 460 Oxford, UK
- 461 Borg N, Department of Neurosurgery, Nebraska Medical Center, Nebraska, USA
- 462 Brannigan J, Department of Clinical neurosciences, University of Cambridge,
- 463 Cambridge, UK
- 464 Brennan PM, Department of Neurosurgery, NHS Lothian, Edinburgh, UK
- 465 Brown C, Department of Neurotrauma, Norfolk and Norwich University hospitals NHS
- 466 Trust, Norwich, UK
- 467 Corbett C, Department of Neurotrauma, Norfolk and Norwich University hospitals NHS
- 468 Trust, Norwich, UK
- 469 Dammers R, Department of Neurosurgery, Erasmus Medical Center, Erasmus MC
- 470 Stroke Center, Rotterdam, the Netherlands
- 471 Das T, Department of Radiology, Cambridge University Hospitals NHS Trust,
- 472 Cambridge, UK
- 473 Feilding E, Department of Aging, Salford Royal NHS Trust, Manchester, UK
- 474 Gamage G, Department of Clinical neurosciences, University of Cambridge,
- 475 Cambridge, UK

- 476 Galea M, Department of Neurosurgery, University Hospital Southampton,
- 477 Southampton, UK
- 478 Glancz L, Department of Neurosurgery, Queens medical centre, Nottingham, UK
- 479 Goacher E, Department of Clinical neurosciences, University of Cambridge,
- 480 Cambridge, UK
- 481 Gooding F, The Brain Tumour Charity, London, UK
- 482 Grange R, Department of Clinical neurosciences, University of Cambridge, Cambridge,
- 483 UK
- 484 Hassan T, Department of Neurosurgery, Alexandria University, Egypt
- 485 Holl DC, Neurosurgery Department Erasmus Medical Centre, Rotterdam, Netherlands
- 486 Jones J, Department of Neurosurgery, St. Georges hospital, London, UK
- 487 Knight R, The Burwell Surgery, Cambridge, UK
- 488 Luoma V, Department of Anaesthesia, National Hospital for Neurology and
- 489 Neurosurgery, London, UK
- 490 Lee KS, Department of Clinical neurosciences, University of Cambridge, Cambridge,
- 491 UK
- 492 Mantle O, Department of Clinical neurosciences, University of Cambridge, Cambridge,
- 493 UK
- 494 Mazzoleni A, Department of Clinical neurosciences, University of Cambridge,
- 495 Cambridge, UK
- 496 Mee H, Department of Clinical Neurosciences, University of Cambridge, Cambridge,
- 497 UK
- 498 Mowforth O, Department of Clinical neurosciences, University of Cambridge,
- 499 Cambridge, UK

- 500 Novak S, Department of Neurology, Cambridge University hospitals NHS Trust,
- 501 Cambridge, UK
- 502 Omar V, Department of Clinical neurosciences, University of Cambridge, Cambridge,
- 503 UK
- 504 Peck G, School of Medicine, Imperial College London, London, UK
- 505 Proffit A, Barts Health NHS Trust, London, UK
- 506 Ramshaw J, Pharmacy department, Cambridge University hospitals NHS Trust,
- 507 Cambridge, UK
- 508 Richardson D, Imperial College Healthcare NHS Trust, London, UK
- 509 Sadek A-R, Department of Neurosurgery, Barking Havering Redbridge University
- 510 Trust, Romford, UK
- 511 Sheehan K, Department of Bone and Joint Health, Blizzard Institute, Queen Mary
- 512 University of London
- 513 Sheppard F, Department of emergency medicine, Norfolk and Norwich University
- 514 Hospitals NHS Trust, Norwich, UK
- 515 Singh N, Department of Neurosurgery, St George's Hospital, London, UK
- 516 Skitterall C, Pharmacy Department, Manchester University NHS Foundation Trust,
- 517 Manchester, UK
- 518 Smit C, Imperial College Healthcare NHS Trust
- 519 Smith M, Department of Emergency Medicine, Salford Royal NHS Foundation Trust,
- 520 Salford, UK
- 521 Sturley R, Department of Geriatric Medicine, St George's, University of London,
- 522 London, UK
- 523 Touzet AY, Department of Clinical neurosciences, University of Cambridge,
- 524 Cambridge, UK

- 525 Uprichard J, Department of Haematology, St George's Hospital, London, UK
- 526 Watson M, Department of Clinical neurosciences, University of Cambridge,
- 527 Cambridge, UK
- 528 Wilson M, Department of neurosurgery, Imperial College Hospital NHS Trust, London,
- 529 UK
- 530 Yeardley V, Central London Community Healthcare NHS Trust, London, UK
- 531

532 Other acknowledgements:

- 533 The authors are grateful to Ms A Mantkelow and Dr C Phillips for their help in organising and
- running the in-person consensus meeting in November 2023.

535 Disclosure statement

- 536 WT has received speaker's fees or sat on advisory boards for: Alexion, Portola, Sobi, Pfizer, Bayer,
- 537 NovoNordisk, Ablynx, Daiichi Sankyo, Takeda, and Sanofi.
- 538 PH is supported by Homerton College and the Health Foundation's grant to the University of Cambridge
- 539 for The Healthcare Improvement Studies Institute (THIS Institute). THIS Institute is supported by the
- 540 Health Foundation, an independent charity committed to bringing about better health and health care for
- 541 people in the UK.
- 542 NRE is supported by a Stroke Association Senior Clinical Lectureship [SA-SCL-MED-22\100006].
- 543 JB reports consulting fees with Synchron.
- 544 VFJN is supported by a NIHR Rosetrees Trust Advanced Fellowship NIHR302544, which is funded in
- 545 partnership by the NIHR and Rosetrees Trust. The views expressed are those of the author(s) and not
- 546 necessarily those of the NIHR, Rosetrees Trust or the Department of Health and Social Care.
- 547 TB is funded by the NIHR Global Health Research Group on Acquired Brain and Spine Injury using UK
- 548 international development funding from the UK Government to support global health research. The views
- 549 expressed in this publication are those of the author(s) and not necessarily those of the NIHR or the UK
- 550 government.

- 551 AJJ is supported by the National Institute for Health Research (NIHR) HealthTech Research Centre in
- 552 Brain Injury based at Cambridge University Hospitals NHS Foundation Trust. The views are those of the
- authors and not neces- sarily those of the NHS, the NIHR, or the Department of Health.
- 554 ODM is supported by an NIHR Academic Clinical Fellowship.
- 555 KS receives funding from UKRI, NIHR and the Royal Osteoporosis Society for research not related to
- the current work.
- 557 JU declares speaker fees and funding from: Bayer, Daiichi-Sankyo, Octapharma.
- 558 DKM is supported by the TBI-REPORTER Project, which is supported by a multi-funder consortium
- 559 consisting of: UK Research and Innovation; National institute for Health and Care Research; UK
- 560 Department of Health and Social Care; UK Ministry of Defence, and Alzheimer's Research UK
- 561 AA is supported by the THIS Institute: THIS Institute is supported by the Health Foundation
- 562 (Grant/Award Number: RHZF/001 RG88620), an independent charity committed to bringing about
- 563 better health and health care for people in the UK.
- 564 JPC is supported by the NIHR Cambridge Biomedical Research Centre (BRC-1215-20014). The views
- 565 expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and
- 566 Social Care.
- 567 IM holds the position of Director of Centre for Research & Improvement, Royal College of Anaesthetists.
- 568 IM is supported by Grant funding from NIHR and charities for research into perioperative care of older
- people.
- 570 AK has been previously supported by NIHR (Dex-CSDH trial).
- 571 FE is a Topic Adviser for NG 232.
- 572
- 573
- 574
- 575
- 576
- 577
- 578
- 579

580 **References**

581 582 583	[1] PJ. Patho and impli	Edlmann E, Giorgi-Coll S, Whitfield PC, Carpenter KLH, Hutchinson physiology of chronic subdural haematoma: Inflammation, angiogenesis ications for pharmacotherapy. <i>J Neuroinflammation</i> . 2017;14(1):1-13.
584 585 586 587	[2] BA, et al. hematom Kingdom	Brennan PM, Kolias AG, Joannides AJ, Shapey J, Marcus HJ, Gregson . The management and outcome for patients with chronic subdural a: a prospective, multicenter, observational cohort study in the United a. <i>J Neurosurg</i> . 2016;127(4):732-739.
588 589 590	[3] Outcome Hematon	Sastry RA, Pertsch N, Tang O, Shao B, Toms SA, Weil RJ. Frailty and s after Craniotomy or Craniectomy for Atraumatic Chronic Subdural na. <i>World Neurosurg</i> . 2021;145:e242-e251.
591 592 593 594 595	[4] Menon D postopera using elec 2020;10(Stubbs DJ, Davies BM, Bashford T, Joannides AJ, Hutchinson PJ, DK, et al. Identification of factors associated with morbidity and ative length of stay in surgically managed chronic subdural haematoma ctronic health records: a retrospective cohort study. <i>BMJ Open</i> . 6):e037385.
596 597 598	[5] chronic s origins. J	Edlmann E, Whitfield P, Kolias AG, Hutchinson PJ. Pathogenesis of ubdural haematoma: a cohort evidencing de novo and transformational <i>Neurotrauma</i> . 2021;38(18):2580-2589.
599 600	[6] hematom	Dumont TM, Rughani AI, Goeckes T, Tranmer BI. Chronic subdural a: A sentinel health event. <i>World Neurosurg</i> . 2013;80(6):889-892.
601 602 603	[7] Elderly: I <i>Reports</i> . 2	Shapey J, Glancz LJ, Brennan PM. Chronic Subdural Haematoma in the Is It Time for a New Paradigm in Management? <i>Current Geriatrics</i> 2016;5:71-77.
604 605 606 607	[8] AJ. Incid effects of 2021;163	Stubbs DJ, Vivian ME, Davies BM, Ercole A, Burnstein R, Joannides ence of chronic subdural haematoma: a single-centre exploration of the an ageing population with a review of the literature. <i>Acta Neurochir</i> . 5(9):2629-2637.
608 609 610	[9] al. Increa Americar	Neifert SN, Chaman EK, Hardigan T, Ladner TR, Feng R, Caridi JM, et ses in Subdural Hematoma with an Aging Population-the Future of a Cerebrovascular Disease. <i>World Neurosurg</i> . 2020;141:e166-e174.
611 612 613	[10] role of pe <i>Anaesthe</i>	Stubbs DJ, Davies BM, Menon DK. Chronic subdural haematoma: the erioperative medicine in a common form of reversible brain injury. <i>sia</i> . 2022;77:21-33.riche
614 615 616 617	[11] Elderly N of chroni group on	Stubbs DJ, Davies B, Hutchinson P, Menon DK, Improving Care in Neurosurgery Initiative (ICENI). Challenges and opportunities in the care c subdural haematoma: perspectives from a multi-disciplinary working the need for change. <i>Br J Neurosurg</i> . 2022;36(5):600-608.
618	[12]	Society of British Neurosurgeons. Neurosurgical Units.

619	https://www.sbns.org.uk/index.php/neurosurgical-units/. Accessed March 22, 2021
620 621 622 623	[13] Stubbs DJ, Khanna S, Davies BM, Vivian ME, Bashford T, Adatia K, et al. Challenges and patient outcomes in chronic subdural haematoma at the level of a regional care system A multi-centre, mixed-methods study from the East of England. <i>Age Ageing</i> . 2024;53(4). doi:10.1093/ageing/afae076
624 625 626	[14] Jones K, Davies BM, Stubbs DJ et al. Can compliment and complaint data inform the care of individuals with chronic subdural haematoma (cSDH)? <i>BMJ Open Quality</i> . 2021;10(3):e001246.
627 628 629 630	[15] The Royal College of Anaesthetists. Guidelines for the Provision of Anaesthetic Services 2024. The Royal College of Anaesthetists. https://www.rcoa.ac.uk/safety-standards-quality/guidance-resources/guidelines- provision-anaesthetic-services. Accessed April 3, 2024
631 632 633 634	 [16] Frailty Guideline Working Group. <i>Perioperative Care of People Living with Frailty</i>. Centre for Perioperative Care; 2021. https://www.cpoc.org.uk/sites/cpoc/files/documents/2021-09/CPOC-BGS-Frailty-Guideline-2021.pdf. Accessed October 8, 2021
635 636 637	 [17] Bullock MR, Chesnut R, Ghajar J, Gordon D, Hartl R, Newell DW, et al. Surgical Management of Acute Subdural Hematomas. <i>Neurosurgery</i>. 2006;58(Supplement):S2-S16 - S2-S24.
638 639 640 641	[18] Stubbs DJ, Davies BM, Dixon-Woods M, Bashford TH, Braude P, Bulters D, et al. Protocol for the development of a multidisciplinary clinical practice guideline for the care of patients with chronic subdural haematoma. <i>Wellcome Open Res.</i> 2023;8:390.
642 643 644 645	 [19] National Institute for Health and Care Excellence. Developing NICE Guidelines: The Manual. Published October 15, 2020. https://www.nice.org.uk/process/pmg20/chapter/introduction#key-principles-for- developing-guidelines. Accessed August 16, 2021
646 647 648 649	[20] The AGREE Next Steps Consortium. <i>Appraisal of Guidelines for Research & Evaluation II Instrument</i> .; 2017. https://www.agreetrust.org/wp-content/uploads/2017/12/AGREE-II-Users-Manual-and-23-item-Instrument-2009-Update-2017.pdf. Accessed August 16, 2021
650 651 652 653	[21] Brannigan JFM, Gillespie CS, Adegboyega G, Watson M, Lee KS, Mazzoleni A, et al. Impact of antithrombotic agents on outcomes in patients requiring surgery for chronic subdural haematoma: a systematic review and meta-analysis. <i>Br J Neurosurg</i> . Published online April 8, 2024:1-8.
654 655 656 657	[22] Adegboyega G, Gillespie CS, Watson M, Lee KS, Brannigan J, Mazzoleni A, et al. Seniority of surgeon in CSDH Recurrence: A systematic review and meta-analysis. <i>World Neurosurg</i> . Published online June 18, 2024. doi:10.1016/j.wneu.2024.06.071
658 659	[23] Gillespie CS, Fung KW, Alam AM, Yanez Touzet A, Dhesi J, Edlmann E, et al. How does research activity align with research need in chronic subdural

660 661	haematoma: a gap analysis of systematic reviews with end-user selected knowledge gaps. <i>Acta Neurochir</i> . Published online May 30, 2023:1-12.
662 663 664 665	[24] National institute for health and care excellence (NIC). 9 Developing and wording guideline recommendations The guidelines manual Guidance NICE. https://www.nice.org.uk/process/pmg6/chapter/developing-and-wording-guideline-recommendations. Accessed April 5, 2024
666 667 668 669	[25] Nathanson MH, Andrzejowski J, Dinsmore J, Eynon CA, Ferguson K, Hooper T, et al. Guidelines for safe transfer of the brain-injured patient: trauma and stroke, 2019: Guidelines from the Association of Anaesthetists and the Neuro Anaesthesia and Critical Care Society. <i>Anaesthesia</i> . 2020;75(2):234-246.
670 671 672 673 674	 [26] National Institute for Health and Care Excellence (NICE). Recommendations Head injury: assessment and early management Guidance NICE. NICE Head injury NG232. https://www.nice.org.uk/guidance/ng232/chapter/Recommendations. Accessed April 3, 2024
675 676 677 678	[27] Klein AA, Meek T, Allcock E, Cook TM, Mincher N, Morris C, et al. Recommendations for standards of monitoring during anaesthesia and recovery 2021: Guideline from the Association of Anaesthetists. <i>Anaesthesia</i> . 2021;76(9):1212-1223.
679 680 681 682	[28] Santarius T, Kirkpatrick PJ, Ganesan D, Chia HL, Jalloh I, Smielewski P, et al. Use of drains versus no drains after burr-hole evacuation of chronic subdural haematoma: a randomised controlled trial. <i>Lancet</i> . 2009;374(9695):1067-1073.
683 684 685 686	[29] Aljabali A, Sharkawy AM, Jaradat B, Serag I, Al-Dardery NM, Abdelhady M, et al. Drainage versus no drainage after burr-hole evacuation of chronic subdural hematoma: a systematic review and meta-analysis of 1961 patients. <i>Neurosurg Rev.</i> 2023;46(1):251.
687 688 689	[30] Qiu Y, Xie M, Duan A, Yin Z, Wang M, Chen X, et al. Comparison of different surgical techniques for chronic subdural hematoma: a network meta- analysis. <i>Front Neurol.</i> 2023;14:1183428.
690 691 692	[31] Hutchinson PJ, Edlmann E, Bulters D, Zolnourian A, Holton P, Suttner N, et al. Trial of Dexamethasone for Chronic Subdural Hematoma. <i>N Engl J Med</i> . 2020;383(27):2616-2627.
693 694 695	[32] Miah IP, Holl DC, Blaauw J, Lingsma HF, den Hertog HM, Jacobs B, et al. Dexamethasone versus Surgery for Chronic Subdural Hematoma. <i>N Engl J Med</i> . 2023;388(24):2230-2240.
696 697 698 699	[33] Edlmann E, Holl DC, Lingsma HF, Bartek J Jr, Bartley A, Duerinck J, et al. Systematic review of current randomised control trials in chronic subdural haematoma and proposal for an international collaborative approach. <i>Acta Neurochir</i> . 2020;162(4):763-776.
700	[34] Rudy RF, Catapano JS, Jadhav AP, Albuquerque FC, Ducruet AF.

701 702	Middle Meningeal Artery Embolization to Treat Chronic Subdural Hematoma. Stroke: Vascular and Interventional Neurology. 2023;3(1):e000490.
703 704 705 706	[35] National Institute for Health and Care Excellence (NICE). Middle meningeal artery embolisation for chronic subdural haematomas. Published December 14, 2023. https://www.nice.org.uk/guidance/ipg779/chapter/1-Recommendations. Accessed March 21, 2024
707 708 709	[36] Peters S, Sukumar K, Blanchard S, Ramasamy A, Malinowski J, Ginex P, et al. Trends in guideline implementation: an updated scoping review. <i>Implement Sci.</i> 2022;17(1):50.
710 711 712	[37] Help establish the content of a guideline for the care of chronic subdural haematoma (cSDH). Thiscovery. https://www.thiscovery.org/project/guideline-csdh-care. Accessed May 3, 2024
713 714 715	[38] Royal College of Physicians. The National Hip Fracture Database. Falls and Fragility Fracture Audit Program (FFFAP). https://www.nhfd.co.uk/. Accessed October 25, 2022
716	
717	
718	
719	
720	
721	
722	
723	
724	
725	
726	
727	
728	
729	
730	
731	
732	

- 733
- 734

735 Figures









740 guideline

738

739



Multidisciplinary guidelines for chronic subdural haematoma: visual summary

Recommendations

67 recommendations, across 8 phases of care. Together advocate integrated care between specialties and specialist/non-specialist units. Full details in paper - key recommendations summarised here



- Delphi of healthcare professionals (n = 139) and analysis of >1000 free-text comments

This is not a validated clinical decision aid and any reliance placed on this information is strictly at the user's own risk

Population

These recommendations apply to patients with the following characteristics:







Significant research required to inform anticoagulant management, non-operative care, middle meningeal artery embolisation, mode of anaesthesia, adjuvant medical care



Emerging work will begin assessing feasibility of guideline implementation. We feel our co-design methodology will likely help secure professional support but more work is needed



Robust data capture, overcoming recognised deficiencies in routine coding solutions, is required. Such a system could also help facilitate national audit, research, and improvement.

Reviewed & endorsed by





Working groups



Working groups had multidisciplinary co-leads. Each group had two facilitated meetings - to refine important clinical questions (1) and draft early recommendations based on collated evidence and expert opinion. All recommendations were then iterated internally among the steering group and externally via a modified Delphi.

Guideline sections

